Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849817 | 1.00 | KMT2A (0.56) | KMT2AMAPK1TBXAS1ALDH1A1MEN1 | |
| SCHEMBL11124265 | 0.82 | KMT2A (0.53) | KMT2AMAPK1TBXAS1ALDH1A1MEN1 | |
| SCHEMBL11124268 | 0.82 | KMT2A (0.53) | KMT2AMAPK1TBXAS1ALDH1A1MEN1 | |
| SCHEMBL11080507 | 0.81 | TBXAS1 (0.53) | KMT2AMAPK1TBXAS1ALDH1A1HCAR2 | |
| SCHEMBL13185586 | 0.81 | ALDH1A1 (0.42) | KMT2AMAPK1TBXAS1ALDH1A1MEN1 | |
| SCHEMBL11080502 | 0.81 | TBXAS1 (0.53) | KMT2AMAPK1TBXAS1ALDH1A1HCAR2 | |
| SCHEMBL10736604 | 0.81 | MAPK1 (0.51) | KMT2AMAPK1TBXAS1ALDH1A1HPGD | |
| SCHEMBL10736596 | 0.81 | MAPK1 (0.51) | KMT2AMAPK1TBXAS1ALDH1A1HPGD | |
| SCHEMBL8920416 | 0.80 | MAPK1 (0.66) | KMT2AMAPK1TBXAS1ALDH1A1MEN1 | |
| SCHEMBL8920408 | 0.80 | MAPK1 (0.66) | KMT2AMAPK1TBXAS1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| WO-2016172545-A1 | CASTRATION-RESISTANT PROSTATE CANCER | NUTECH VENTURES (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| US-5039684-A | Absorption when administered orally | VALEAS S. P. A. (IT) | 1991-08-13 | — | — | US | disclosed |
| EP-0384450-A1 | Tetrazole amide derivatives of heterocyclic alkenyl acids and their use as antiallergic substances | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1990-08-29 | — | — | EP | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | KMT2A 1823/4885MAPK1 3516/4885TBXAS1 16/4885 |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | UGDH, G6PD, DPYD | KMT2A 1415/4885MAPK1 2207/4885TBXAS1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.